The incidence of inflammatory bowel disease (IBD) has been increasing in China. The main therapeutic drugs include aminosalicylic acid, glucocorticoids, immunosuppressants and biological agents. However, all these drugs have certain limitations, such as poor therapeutic efficacy and evident side effects, etc. Therefore, it is urgent to...
On October 12, the finals of the theme performance of cancer prevention and treatment, and infectious disease prevention and control of New Area Health Popular Science Works Solicitation Competition 2023 was held in the First Affiliated Hospital （FAH） of Xi’an Jiaotong University (XJTU).At the meeting, Ma Xinge, Party Secretary of t...
On September 20, 2023, "Digital Health Innovation Conference in conjunction with the 6th National Smart Health Innovation Final Competition" was officially held in Harbin, aiming to actively respond to the strategies of "Healthy China" and "Quality Workforce", and the guidance of the policy planning of "Digital China", give play to the...
On September 29, 2023, during the Mid-Autumn Festival, Xie Xinfang, a young physician from Department of Nephrology of the First Affiliated Hospital (FAH) of Xi’an Jiaotong University (XJTU), was invited to give a presentation entitled New Insight into Poly-IgA1 Formation-Two Potential Therapies at the 17th International Symposium on ...
Recently, under intimate cooperation of Department of Anesthesiology and Perioperative Medicine and Department of Ultrasound Medicine, Department of Cardiovascular Surgery from the First Affiliated Hospital (FAH) of Xi'an Jiaotong University (XJTU) successfully performed beating-heart implantation of the smallest and lightest China-mad...
